A specific structure and high richness characterize intestinal microbiota of HIV-exposed seronegative individuals.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 04 10 2021
accepted: 15 11 2021
entrez: 2 12 2021
pubmed: 3 12 2021
medline: 20 1 2022
Statut: epublish

Résumé

Intestinal microbiota facilitates food breakdown for energy metabolism and influences the immune response, maintaining mucosal homeostasis. Overall, HIV infection is associated with intestinal dysbiosis and immune activation, which has been related to seroconversion in HIV-exposed individuals. However, it is unclear whether microbiota dysbiosis is the cause or the effect of immune alterations and disease progression or if it could modulate the risk of acquiring the HIV infection. We characterize the intestinal microbiota and determine its association with immune regulation in HIV-exposed seronegative individuals (HESN), HIV-infected progressors (HIV+), and healthy control (HC) subjects. For this, feces and blood were collected. The microbiota composition of HESN showed a significantly higher alpha (p = 0.040) and beta diversity (p = 0.006) compared to HC, but no differences were found compared to HIV+. A lower Treg percentage was observed in HESN (1.77%) than HC (2.98%) and HIV+ (4.02%), with enrichment of the genus Butyrivibrio (p = 0.029) being characteristic of this profile. Moreover, we found that Megasphaera (p = 0.017) and Victivallis (p = 0.0029) also are enriched in the microbiota composition in HESN compared to HC and HIV+ subjects. Interestingly, an increase in Succinivibrio and Prevotella, and a reduction in Bacteroides genus, which is typical of HIV-infected individuals, were observed in both HESN and HIV+, compared to HC. Thus, HESNs have a microbiota profile, similar to that observed in HIV+, most likely because HESN are cohabiting with their HIV+ partners.

Identifiants

pubmed: 34855852
doi: 10.1371/journal.pone.0260729
pii: PONE-D-21-31936
pmc: PMC8638974
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0260729

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

AIDS Res Hum Retroviruses. 2016 Feb;32(2):129-33
pubmed: 26414485
Elife. 2013 Apr 16;2:e00458
pubmed: 23599893
AIDS. 2014 Mar 13;28(5):753-60
pubmed: 24335481
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Mucosal Immunol. 2014 Jul;7(4):983-94
pubmed: 24399150
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188
pubmed: 28449106
J Immunol. 2011 Sep 1;187(5):2278-90
pubmed: 21775683
Clin Exp Immunol. 2011 May;164(2):158-69
pubmed: 21413945
PLoS Pathog. 2021 Apr 26;17(4):e1009533
pubmed: 33901266
Sci Rep. 2019 Jan 24;9(1):703
pubmed: 30679677
Mucosal Immunol. 2014 Mar;7(2):268-79
pubmed: 23801306
Sci Rep. 2021 Jan 13;11(1):960
pubmed: 33441754
J Infect Dis. 2016 Feb 15;213(4):569-73
pubmed: 26310308
J Infect Dis. 2009 May 1;199(9):1318-22
pubmed: 19301980
Int J Syst Evol Microbiol. 2019 Jun;71(3):
pubmed: 33616513
Curr HIV Res. 2019;17(1):13-25
pubmed: 30854974
Int J Syst Evol Microbiol. 2008 Sep;58(Pt 9):2041-5
pubmed: 18768601
Microbes Infect. 2016 Mar;18(3):211-9
pubmed: 26548606
J Infect Dis. 2015 Jan 1;211(1):19-27
pubmed: 25057045
Am J Reprod Immunol. 2014 Aug;72(2):219-27
pubmed: 24428610
J Infect Dis. 2021 Oct 13;224(7):1247-1256
pubmed: 33544868
EBioMedicine. 2016 Jan 28;5:135-46
pubmed: 27077120
Cells. 2021 Feb 13;10(2):
pubmed: 33668457
Sci Rep. 2015 Jun 23;5:11511
pubmed: 26099972
J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1079-86
pubmed: 24304358
Int J Syst Evol Microbiol. 2003 Jan;53(Pt 1):211-215
pubmed: 12656175
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
PLoS Pathog. 2014 Feb 20;10(2):e1003829
pubmed: 24586144
Cell Host Microbe. 2013 Sep 11;14(3):329-39
pubmed: 24034618
PLoS One. 2014 May 09;9(5):e96844
pubmed: 24817204
Microbes Infect. 2020 Sep;22(8):371-374
pubmed: 31816393
Immunol Res. 2016 Jun;64(3):765-74
pubmed: 26724942
Curr HIV/AIDS Rep. 2019 Jun;16(3):204-213
pubmed: 31037552
PeerJ. 2019 Jan 7;7:e6200
pubmed: 30643702
PLoS One. 2020 Dec 4;15(12):e0243609
pubmed: 33275647
Mucosal Immunol. 2015 Jul;8(4):760-72
pubmed: 25407519
Lancet Infect Dis. 2018 May;18(5):554-564
pubmed: 29396006
PLoS Pathog. 2019 Apr 4;15(4):e1007611
pubmed: 30947289
PLoS One. 2018 Jul 27;13(7):e0201073
pubmed: 30052654
mSphere. 2020 Feb 5;5(1):
pubmed: 32024712
Sci Rep. 2017 Jul 24;7(1):6269
pubmed: 28740260
Science. 2012 Jun 8;336(6086):1268-73
pubmed: 22674334
Acta Trop. 2018 Feb;178:327-332
pubmed: 29154947
Clin Infect Dis. 2020 Nov 5;71(8):e359-e367
pubmed: 31894240
Nat Protoc. 2020 Mar;15(3):799-821
pubmed: 31942082
Trends Immunol. 2013 Sep;34(9):423-30
pubmed: 23957963
AIDS Res Hum Retroviruses. 2013 Jan;29(1):13-9
pubmed: 23020644
Microbiome. 2019 Sep 13;7(1):130
pubmed: 31519223
Front Immunol. 2020 Apr 09;11:645
pubmed: 32328074

Auteurs

Tulio J Lopera (TJ)

Facultad de Medicina, Grupo Inmunovirología, Universidad de Antioquia UdeA, Medellín, Colombia.

Jorge A Lujan (JA)

Facultad de Medicina, Grupo Inmunovirología, Universidad de Antioquia UdeA, Medellín, Colombia.

Eduardo Zurek (E)

Department of System Engineering, Universidad del Norte, Barranquilla, Colombia.

Wildeman Zapata (W)

Facultad de Medicina, Grupo Inmunovirología, Universidad de Antioquia UdeA, Medellín, Colombia.
Facultad de Medicina, Grupo Infettare, Universidad Cooperativa de Colombia, Medellín, Colombia.

Juan C Hernandez (JC)

Facultad de Medicina, Grupo Infettare, Universidad Cooperativa de Colombia, Medellín, Colombia.

Miguel A Toro (MA)

Facultad de Medicina, Centro Nacional de Secuenciación Genómica -CNSG, Sede de Investigación Universitaria -SIU, Universidad de Antioquia UdeA, Medellin, Colombia.
Facultad de Medicina, Grupo de Parasitología, Universidad de Antioquia, Medellín, Colombia.

Juan F Alzate (JF)

Facultad de Medicina, Centro Nacional de Secuenciación Genómica -CNSG, Sede de Investigación Universitaria -SIU, Universidad de Antioquia UdeA, Medellin, Colombia.

Natalia A Taborda (NA)

Facultad de Medicina, Grupo Inmunovirología, Universidad de Antioquia UdeA, Medellín, Colombia.
Facultad de Ciencias de la Salud, Grupo de Investigaciones Biomédicas Uniremington, Programa de Medicina, Corporación Universitaria Remington, Medellín, Colombia.

Maria T Rugeles (MT)

Facultad de Medicina, Grupo Inmunovirología, Universidad de Antioquia UdeA, Medellín, Colombia.

Wbeimar Aguilar-Jimenez (W)

Facultad de Medicina, Grupo Inmunovirología, Universidad de Antioquia UdeA, Medellín, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH